Pacylex's NMT inhibitor, zelenirstat, was highlighted in a new Nature Cancer article on ADCs

New Nature Article, link here: https://www.nature.com/articles/s43018-026-01152-z, has highlighted the potential in our approach of generating ADCs from our NMT inhibitor, zelenirstat.

"Pacylex, too, is now exploring zelenirstat as an ADC payload, encouraged by preclinical data reported in November 2025 suggesting that the targeted approach could boost potency as much as 1,000-fold, enabling much lower effective doses." -

New payloads drive next-gen antibody–drug conjugates - Nature Cancer April 23, 2026

‍

Image designed by Freepik.